Literature DB >> 34963734

Mucormycosis in COVID-19: Is Zinc a Silent Killer in India?

Sayan Nath1, Dalim K Baidya1.   

Abstract

How to cite this article: Nath S, Baidya DK. Mucormycosis in COVID-19: Is Zinc a Silent Killer in India? Indian J Crit Care Med 2021;25(9):1079-1080.
Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.

Entities:  

Keywords:  COVID-19; Mucormycosis; Zinc

Year:  2021        PMID: 34963734      PMCID: PMC8664031          DOI: 10.5005/jp-journals-10071-23938

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


The second wave of coronavirus disease 2019 (COVID-19) in India has hit the country hard with over 6.6 million people infected just in the month of April 2021.[1] Recently, a particular concern in COVID-19-affected patients has been the rising incidence of mucormycosis.[2] The estimated prevalence of mucormycosis in India is around 70 times higher than the rest of the world. Diabetes mellitus is the most common risk factor, followed by hematological malignancy and solid organ transplant.[3] The immune dysregulation due to reduced numbers of T lymphocytes, CD4+T, and CD8+T cells in COVID-19 may alter the innate immunity that facilitates opportunistic fungal growth in these patients. The recent surge in cases of mucormycosis has been linked to rampant usage of corticosteroids, hyperglycemia, broad-spectrum antibiotics, and monoclonal antibodies on a background of an already suppressed immune system in these patients.[4] However, one particular factor that has been commonly overlooked is the uncontrolled and unmonitored use of zinc in COVID-19. Zinc, which was initially thought to be helpful in the prevention and treatment of COVID-19 owing to the hypothesized antiviral activity, was later found to be ineffective for the same.[5] Long-term use of large doses of zinc has concerns of serious adverse effects like copper deficiency and neurological deficits, and major guidelines have recommended against the use of zinc in doses above its recommended dietary allowance for the treatment of COVID-19.[6] However, many regional guidelines in India continue to include high dose zinc as a common treatment across several categories of COVID-19.[7,8] Zinc being available as an over the counter medication has facilitated general population to consume it in large quantity with hope of protection against COVID-19 due to widespread circulation of such guidelines through social media. Zinc is known as a common growth factor for different pathological fungi, including Mucorales.[9] Zinc influences diverse mechanisms of fungal pathogenesis by directly regulating fungal proteins required to infect mammalian hosts.[10] Zinc deprivation by the host is an important antifungal mechanism,[11] and zinc chelators have been shown to inhibit different fungal growth, including Mucorales, both in vitro and in vivo.[12,13] It is possible that the excess availability of zinc in the body owing to its incessant use by COVID-19 patients might be adding to the risk of fungal infections like mucormycosis in these patients. To determine whether Zinc has a constant and significant association with mucormycosis in COVID-19-affected patients, further studies are needed. But since zinc is a definite facilitator of fungal infection, in the absence of its clear-cut benefit against the COVID-19 disease, authorities and expert panels in India should read out words of caution and raise awareness against rampant usage of high doses of zinc and should exercise measures to prevent uncontrolled availability of zinc tablets over-the-counter in the country.
  9 in total

1.  Fungal susceptibility to zinc deprivation.

Authors:  Sarah J Lulloff; Beth L Hahn; Peter G Sohnle
Journal:  J Lab Clin Med       Date:  2004-10

2.  In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species.

Authors:  Florencia Leonardelli; Daiana Macedo; Catiana Dudiuk; Laura Theill; Matias S Cabeza; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 3.  An evolutionary perspective on zinc uptake by human fungal pathogens.

Authors:  Duncan Wilson
Journal:  Metallomics       Date:  2015-06       Impact factor: 4.526

4.  Novel Zinc-Attenuating Compounds as Potent Broad-Spectrum Antifungal Agents with In Vitro and In Vivo Efficacy.

Authors:  Karen A O'Hanlon Cohrt; Laura Marín; Lasse Kjellerup; Johannes D Clausen; William Dalby-Brown; José Antonio Calera; Anne-Marie Lund Winther
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Invasive fungal diseases during COVID-19: We should be prepared.

Authors:  J-P Gangneux; M-E Bougnoux; E Dannaoui; M Cornet; J R Zahar
Journal:  J Mycol Med       Date:  2020-04-06       Impact factor: 2.391

6.  Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.

Authors:  Suma Thomas; Divyang Patel; Barbara Bittel; Kathy Wolski; Qiuqing Wang; Anirudh Kumar; Zachary J Il'Giovine; Reena Mehra; Carla McWilliams; Steve E Nissen; Milind Y Desai
Journal:  JAMA Netw Open       Date:  2021-02-01

7.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Shashank R Joshi; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-21

Review 8.  Fungal zinc metabolism and its connections to virulence.

Authors:  Charley C Staats; Lívia Kmetzsch; Augusto Schrank; Marilene H Vainstein
Journal:  Front Cell Infect Microbiol       Date:  2013-10-14       Impact factor: 5.293

Review 9.  Epidemiology of Mucormycosis in India.

Authors:  Hariprasath Prakash; Arunaloke Chakrabarti
Journal:  Microorganisms       Date:  2021-03-04
  9 in total
  2 in total

Review 1.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 2.  Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents.

Authors:  Mohd Imran; Waseem Fatima; A Khuzaim Alzahrani; Nida Suhail; Mohammed Kanan Alshammari; Abdulrahman A Alghitran; Fayez Nafea Alshammari; Mohammed M Ghoneim; Sultan Alshehri; Faiyaz Shakeel
Journal:  Nutrients       Date:  2022-03-14       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.